BUPIVACAINE HYDROCHLORIDE

/static/temp/default.svg

Search structure


Trade Names	BUPIVACAINE HYDROCHLORIDE BUPIVACAINE HYDROCHLORIDE KIT BUPIVACAINE HYDROCHLORIDE PRESERVATIVE FREE MARCAINE MARCAINE HYDROCHLORIDE MARCAINE HYDROCHLORIDE PRESERVATIVE FREE SENSORCAINE
Synonyms	AH-2250 Bupivac hcl Bupivacaine hcl Bupivacaine hydrochloride Bupivacaine hydrochloride hydrate Bupivacaine hydrochloride kit Bupivacaine hydrochloride monohydrate Bupivacaine hydrochloride preservative free Bupivacaine hydrochloride rs Bupivacaini hydrochloridum Carbostesin LAC-43 Marcain Marcaine Marcaine hydrochloride
Status
Molecule Category	Salt-form
UNII	7TQO7W3VT8
EPA CompTox	DTXSID501323779
Parent Compound:	BUPIVACAINE

Structure


InChI Key	SIEYLFHKZGLBNX-UHFFFAOYSA-N
Smiles	CCCCN1CCCCC1C(=O)Nc1c(C)cccc1C.Cl
InChI	InChI=1S/C18H28N2O.ClH/c1-4-5-12-20-13-7-6-11-16(20)18(21)19-17-14(2)9-8-10-15(17)3;/h8-10,16H,4-7,11-13H2,1-3H3,(H,19,21);1H

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C18H29ClN2O
Molecular Weight	324.9
AlogP	3.9
Hydrogen Bond Acceptor	2.0
Hydrogen Bond Donor	1.0
Number of Rotational Bond	5.0
Polar Surface Area	32.34
Molecular species	NEUTRAL
Aromatic Rings	1.0
Heavy Atoms	21.0

Pharmacology

Mechanism of Action	Action	Reference
Sodium channel protein type IV alpha subunit blocker	BLOCKER	PubMed

Targets	EC50(nM)	IC50(nM)	Kd(nM)	Ki(nM)	Inhibition(%)
Transporter Electrochemical transporter SLC superfamily of solute carriers SLC21/SLCO family of organic anion transporting polypeptides	-	-	-	-	94.2-97.15

	EC50(nM)	IC50(nM)	Kd(nM)	Ki(nM)	Inhibition(%)
Cricetulus griseus	-	-	-	-	94.2-97.15

Target Conservation


Protein: Sodium channel protein type IV alpha subunit Description: Sodium channel protein type 4 subunit alpha Organism : Homo sapiens P35499 ENSG00000007314

Cross References

Resources	Reference
CAS NUMBER	73360-54-0
ChEBI	77441
ChEMBL	CHEMBL1200396
FDA SRS	7TQO7W3VT8
PubChem	5282419
SureChEMBL	SCHEMBL34374
ZINC	ZINC01530814

CONTENTS

EcoDrug+ was developed under the PREMIER Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information EcoDrug+ contains.

Elements of EcoDrug+ were developed under the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT Center for Science Ltd is thanked for providing computational resources. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

Content of EcoDrug+ is provided without guarantee for correctness.

Cite Us:

Ashenafi Legehar, Siobhán Monaghan, Mael Briand, Akseli Niemelä, Leo Ghemtio, Ziaurrehman Tanoli, A Ross Brown, Charles R Tyler, Henri Xhaard, EcoDrug PLUS: an advanced database for drug target conservation analysis and environmental risk assessment, Nucleic Acids Research, Volume 54, Issue D1, 6 January 2026, Pages D1397–D1404, https://doi.org/10.1093/nar/gkaf1251

This work is licensed under Creative Commons Attribution-ShareAlike 4.0 International License

Last update: Monday, 23^rd March 2026